Cargando…

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition

OBJECTIVE: Evaluate the effects of two dipeptidyl peptidase-IV (DPP-4) inhibitors, sitagliptin and vildagliptin, known to have different efficacy on mean amplitude of glycemic excursions (MAGE), on oxidative stress, and on systemic inflammatory markers in patients with type 2 diabetes. RESEARCH DESI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizzo, Maria Rosaria, Barbieri, Michelangela, Marfella, Raffaele, Paolisso, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447848/ https://www.ncbi.nlm.nih.gov/pubmed/22688551 http://dx.doi.org/10.2337/dc12-0199

Ejemplares similares

Response to Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082
por: Rizzo, Maria Rosaria, et al.
Publicado: (2013)

Bariatric Surgery Reduces Oxidative Stress by Blunting 24-h Acute Glucose Fluctuations in Type 2 Diabetic Obese Patients
por: Marfella, Raffaele, et al.
Publicado: (2010)

Relationships Between Daily Acute Glucose Fluctuations and Cognitive Performance Among Aged Type 2 Diabetic Patients
por: Rizzo, Maria Rosaria, et al.
Publicado: (2010)

Dipeptidyl Peptidase 4 Inhibition May Facilitate Healing of Chronic Foot Ulcers in Patients with Type 2 Diabetes
por: Marfella, Raffaele, et al.
Publicado: (2012)

Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes
por: Sardu, Celestino, et al.
Publicado: (2016)

Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082
por: DeVries, J. Hans
Publicado: (2013)

Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082
por: Makdissi, Antoine, et al.
Publicado: (2013)

Association of Genetic Variation in Adaptor Protein APPL1/APPL2 Loci with Non-Alcoholic Fatty Liver Disease
por: Barbieri, Michelangela, et al.
Publicado: (2013)

Mediterranean Diet, Telomere Maintenance and Health Status among Elderly
por: Boccardi, Virginia, et al.
Publicado: (2013)

Awaking Blood Pressure Surge and Progression to Microalbuminuria in Type 2 Normotensive Diabetic Patients
por: Barbieri, Michelangela, et al.
Publicado: (2016)

Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome
por: Sardu, Celestino, et al.
Publicado: (2017)

miR-21 in Human Cardiomyopathies
por: Surina,, et al.
Publicado: (2021)

Corrigendum: miR-21 in Human Cardiomyopathies
por: Surina,, et al.
Publicado: (2022)

Adiponectin Related Vascular and Cardiac Benefits in Obesity: Is There a Role for an Epigenetically Regulated Mechanism?
por: Fontanella, Rosaria Anna, et al.
Publicado: (2021)

Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes
por: Sardu, Celestino, et al.
Publicado: (2017)

ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause: Therapeutic and prognostic implications. The ELICA randomized trial
por: Sardu, Celestino, et al.
Publicado: (2018)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate
por: Sardu, Celestino, et al.
Publicado: (2018)

Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome
por: Sardu, Celestino, et al.
Publicado: (2018)

Serum adiponectin levels are associated with worse cognitive function in postmenopausal women
por: De Franciscis, Pasquale, et al.
Publicado: (2017)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
por: Scisciola, Lucia, et al.
Publicado: (2023)

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)

Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure
por: Salles, Thiago A., et al.
Publicado: (2015)

Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis
por: Larrinaga, Gorka, et al.
Publicado: (2015)

Hyperglycaemia on admission to hospital and COVID-19
por: Sardu, Celestino, et al.
Publicado: (2020)

Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?
por: Sardu, Celestino, et al.
Publicado: (2020)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose
por: Das, Siddhartha Shankar, et al.
Publicado: (2014)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
por: Nojima, Hiroyuki, et al.
Publicado: (2016)

Constituents of Coreopsis lanceolata Flower and Their Dipeptidyl Peptidase IV Inhibitory Effects
por: Kim, Bo-Ram, et al.
Publicado: (2020)

CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
por: Pan, Kelsey, et al.
Publicado: (2021)

Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease
por: Zhang, Yuanyuan, et al.
Publicado: (2022)

Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV
por: Rohani, et al.
Publicado: (2023)

Structural Similarities, in Relation with the Cross-Reactivity, of Hymenoptera Allergenic Dipeptidyl Peptidases IV—An Overall Comparison Including a New Dipeptidyl Peptidase IV Sequence from Vespa velutina
por: Monsalve, Rafael I., et al.
Publicado: (2023)

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
por: Trzaskalski, Natasha A, et al.
Publicado: (2020)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin
por: Sardu, Celestino, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sdgd2fu7h50osjrlvttgbsqdl7